2023
Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma
Potnis K, Di M, Isufi I, Gowda L, Seropian S, Foss F, Forman H, Huntington S. Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma. Blood Advances 2023, 7: 801-810. PMID: 36342852, PMCID: PMC10011202, DOI: 10.1182/bloodadvances.2022008097.Peer-Reviewed Original ResearchConceptsCAR T-cell therapyT-cell therapyQuality-adjusted life yearsIncremental cost-effectiveness ratioCAR T cellsChimeric antigen receptor T-cell therapySOC therapyFollicular lymphomaT cellsLife yearsR FLRefractory follicular lymphomaT cell strategiesThird-line settingLines of therapyIncremental clinical benefitUS payer perspectiveCost-effectiveness ratioTherapy remissionUnselected patientsCare therapyClinical benefitClinical trialsTreatment strategiesPayer perspective
2015
Evaluation for Blunt Cerebrovascular Injury: Review of the Literature and a Cost-Effectiveness Analysis
Malhotra A, Wu X, Kalra VB, Schindler J, Matouk CC, Forman HP. Evaluation for Blunt Cerebrovascular Injury: Review of the Literature and a Cost-Effectiveness Analysis. American Journal Of Neuroradiology 2015, 37: 330-335. PMID: 26450540, PMCID: PMC7959958, DOI: 10.3174/ajnr.a4515.Peer-Reviewed Original ResearchConceptsCost-effective imaging strategyNet monetary benefitHealth care payer perspectiveIncremental cost-effectiveness ratioCare payer perspectiveCost-effectiveness analysisCost-effective strategyCost-effectiveness ratioEconomic evaluationMonetary benefitsDominant strategyMain indicatorsPayer perspectiveSelective DSAComparable utilityUtility perspectiveDecision tree analysisSelective anticoagulationSensitivity analysisCostImmense controversyHigh costCTA sensitivityParameter valuesHorizon